Selecting the Optimal Immunotherapy Regimen in Driver-Negative Metastatic NSCLC

The treatment landscape of driver-negative non-small-cell lung cancer (NSCLC) is rapidly evolving. Immune-checkpoint inhibitors, specifically those targeting PD-1 or PD-L1, have demonstrated durable efficacy in a subset of patients with NSCLC, and these agents have become the cornerstone of first-line therapy. In this review, the authors discuss the current treatment landscape and detail an approach to first-line immunotherapy regimen selection for patients with advanced-stage, driver-negative NSCLC.